← Leaderboards
Scott G Hansen
Oregon Health & Science University
$8,205,228
Attributed
$10,656,679
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,656,679 · 6
By mechanism
R01$7,739,156 · 2
P01$2,328,746 · 2
R21$493,429 · 1
F32$95,348 · 1
Top collaborators
- Jonah B. Sacha7 shared
Most similar at Oregon Health & Science University
Same institution · by research overlap
- Jonah B. Sacha$34,199,132
- Christoph Adrian Kahl$3,227,415
- David C. Johnson$20,134,941
- Jay A Nelson$38,488,581
- Justin Greene$1,359,279
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseInfectionTissuesVaccinesImmune ResponseCytomegalovirusVaccinatedMacaca MulattaT Cell ResponseImmunologicsVectorImmuneCd8-Positive T-LymphocytesSiteHiv VaccinePathogenicityBaseCellsT-LymphocyteMediatingClinical TranslationSiv VaccinesGenetic TranscriptionAutopsy
Grant awards (17)
Project 2: Characterization of the in vivo T cell (and overall immune) interception of primary SIV infection after vaccination with differentially response programmed RhCMV/SIV vectors$449,666
P01 · FY2025 · AI · contact PI
Project 2: Characterization of the in vivo T cell (and overall immune) interception of primary SIV infection after vaccination with differentially response programmed RhCMV/SIV vectors$564,350
P01 · FY2024 · AI · contact PI
Understanding Unconventional CD8+ T cell Responses in Protection from HIV$795,947
R01 · FY2023 · AI
Project 2: Characterization of the in vivo T cell (and overall immune) interception of primary SIV infection after vaccination with differentially response programmed RhCMV/SIV vectors$559,267
P01 · FY2023 · AI · contact PI
Project 2: Characterization of the in vivo T cell (and overall immune) interception of primary SIV infection after vaccination with differentially response programmed RhCMV/SIV vectors$755,463
P01 · FY2022 · AI · contact PI
Understanding Unconventional CD8+ T cell Responses in Protection from HIV$800,450
R01 · FY2021 · AI
Understanding Unconventional CD8+ T cell Responses in Protection from HIV$1,146,291
R01 · FY2020 · AI
Understanding Unconventional CD8+ T cell Responses in Protection from HIV$819,581
R01 · FY2019 · AI
Efficacy of Strain 68-1 RhCMV Vectors Expressing 5' Leader Polypeptides$790,163
R01 · FY2019 · AI · contact PI
Understanding Unconventional CD8+ T cell Responses in Protection from HIV$847,205
R01 · FY2018 · AI
Efficacy of Strain 68-1 RhCMV Vectors Expressing 5' Leader Polypeptides$800,715
R01 · FY2018 · AI · contact PI
Efficacy of Strain 68-1 RhCMV Vectors Expressing 5' Leader Polypeptides$856,238
R01 · FY2017 · AI · contact PI
Impact of retroviral infection on non-classical, mycobacteria-specific T cells.$268,590
R21 · FY2017 · AI
Efficacy of Strain 68-1 RhCMV Vectors Expressing 5' Leader Polypeptides$882,566
R01 · FY2016 · AI · contact PI
Impact of retroviral infection on non-classical, mycobacteria-specific T cells.$224,839
R21 · FY2016 · AI
Growth of rheusus cytomegalovirus in macrophages$48,928
F32 · FY2004 · AI
Growth of rheusus cytomegalovirus in macrophages$46,420
F32 · FY2003 · AI